Application for admission to trading - update

ABCAM PLC

("Abcam" or "the Company")

Application for admission to trading - update

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that further to the announcement made yesterday, admission to trading of the 881,030 new ordinary shares of 0.2p each in the Company issued in connection with the acquisition of the entire issued share capital of AxioMx, Inc. is expected to occur on or around 16th November 2015.

For further information please contact:

Notes to Editors

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 130 countries. The Company was founded in 1998, and now employs over 820 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com